Abilify for kids: early safety trial shows promise
NCT ID NCT00102479
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the safety and tolerability of aripiprazole (Abilify) in 21 children and adolescents aged 10 to 17 with schizophrenia or mania. Participants took daily doses of 2 to 30 mg for 14 days. The main goals were to see how many could tolerate the highest dose without side effects and to measure drug levels in the blood. This early-phase trial helps guide future dosing in younger patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Aripiprazole (Abilify)
- What this could lead to
- If successful, this study could help doctors understand safe dosing of aripiprazole for young people with schizophrenia or bipolar disorder.
- What could go wrong
- This is a very small, early-phase study (21 participants) focused on safety, not on how well the drug works. Results may not apply to all children or guarantee effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?